Severe and prevalent disorders seen across all ethnicities
Enhanced SMA testing to help identify silent carriers
ACOG- and ACMG-recommended disorders
Full gene sequencing with deletion and duplication analysis
Actionable results; no reporting of variants of unknown significance
The ability to order a curated panel or customize an order for a specific patient
Results in 10 to 21 days, on average
Analyzes 3 genesORDER
Analyzes 47 genes
Analyzes 289 genesORDER
|Test description||Includes the most commonly ordered genes associated with disorders seen across all ethnicities||Appropriate for patients of all ethnicities who want to screen for common and severe disorders||For patients of all ethnicities who want an expanded assessment of their risk of having an affected child|
|ACOG- & ACMG-recommendations||
|Disorders included||Cystic fibrosis
Spinal muscular atrophy
Fragile X syndrome
|All disorders on the Core carrier screen plus:
||All disorders on the Broad carrier screen plus:
|# of X-linked disorders||1*||5*||21*|
*Panels can be ordered without X-linked disorders.
We’re here to help answer you and your patients’ questions and provide support every step of the way. Invitae’s team of genetic counselors are available to:
Invitae's comprehensive clinical support lets you spend more time doing what you do best—caring for your patients
Our team of genetics experts is available to answer patients general questions about testing
Practice Bulletin No. 163: Screening for fetal aneuploidy. Obstet Gynecol. 2016;127(5):979-81.
Gregg AR, Skotko BG, Benkendorf JL et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18(10):1056-65.